Trial Outcomes & Findings for Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) (NCT NCT05804045)
NCT ID: NCT05804045
Last Updated: 2026-05-04
Results Overview
Assessed by central read using Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
ACTIVE_NOT_RECRUITING
PHASE3
94 participants
Baseline to Week 25
2026-05-04
Participant Flow
Participant milestones
| Measure |
Part 1- Placebo, Part 2/Part 3- Pimicotinib(ABSK021)
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
Placebo: capsule Pimicotinib(ABSK021): capsule
|
Part 1/Part 2/Part 3- Pimicotinib(ABSK021)
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
Pimicotinib(ABSK021): capsule
|
|---|---|---|
|
Week 1 to Week 24
STARTED
|
31
|
63
|
|
Week 1 to Week 24
COMPLETED
|
29
|
59
|
|
Week 1 to Week 24
NOT COMPLETED
|
2
|
4
|
|
Week 25 to Week 48
STARTED
|
31
|
52
|
|
Week 25 to Week 48
COMPLETED
|
11
|
28
|
|
Week 25 to Week 48
NOT COMPLETED
|
20
|
24
|
|
Week 49 to End of Study
STARTED
|
11
|
23
|
|
Week 49 to End of Study
COMPLETED
|
0
|
0
|
|
Week 49 to End of Study
NOT COMPLETED
|
11
|
23
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Baseline characteristics by cohort
| Measure |
Part 1/Part 2/Part 3- Pimicotinib(ABSK021)
n=63 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
Pimicotinib(ABSK021): capsule
|
Part 1- Placebo, Part 2/Part 3- Pimicotinib(ABSK021)
n=31 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
Placebo: capsule Pimicotinib(ABSK021): capsule
|
Total
n=94 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
42.6 years
STANDARD_DEVIATION 14.30 • n=54 Participants
|
38.3 years
STANDARD_DEVIATION 12.46 • n=60 Participants
|
41.2 years
STANDARD_DEVIATION 13.79 • n=114 Participants
|
|
Sex: Female, Male
Female
|
45 Participants
n=54 Participants
|
19 Participants
n=60 Participants
|
64 Participants
n=114 Participants
|
|
Sex: Female, Male
Male
|
18 Participants
n=54 Participants
|
12 Participants
n=60 Participants
|
30 Participants
n=114 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=54 Participants
|
0 Participants
n=60 Participants
|
0 Participants
n=114 Participants
|
|
Race (NIH/OMB)
Asian
|
32 Participants
n=54 Participants
|
16 Participants
n=60 Participants
|
48 Participants
n=114 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=54 Participants
|
0 Participants
n=60 Participants
|
0 Participants
n=114 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=54 Participants
|
2 Participants
n=60 Participants
|
5 Participants
n=114 Participants
|
|
Race (NIH/OMB)
White
|
26 Participants
n=54 Participants
|
11 Participants
n=60 Participants
|
37 Participants
n=114 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=54 Participants
|
0 Participants
n=60 Participants
|
1 Participants
n=114 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=54 Participants
|
2 Participants
n=60 Participants
|
3 Participants
n=114 Participants
|
|
Region of Enrollment
Canada
|
6 participants
n=54 Participants
|
4 participants
n=60 Participants
|
10 participants
n=114 Participants
|
|
Region of Enrollment
Netherlands
|
5 participants
n=54 Participants
|
5 participants
n=60 Participants
|
10 participants
n=114 Participants
|
|
Region of Enrollment
United States
|
8 participants
n=54 Participants
|
3 participants
n=60 Participants
|
11 participants
n=114 Participants
|
|
Region of Enrollment
China
|
31 participants
n=54 Participants
|
14 participants
n=60 Participants
|
45 participants
n=114 Participants
|
|
Region of Enrollment
Poland
|
2 participants
n=54 Participants
|
0 participants
n=60 Participants
|
2 participants
n=114 Participants
|
|
Region of Enrollment
Italy
|
4 participants
n=54 Participants
|
2 participants
n=60 Participants
|
6 participants
n=114 Participants
|
|
Region of Enrollment
Spain
|
7 participants
n=54 Participants
|
3 participants
n=60 Participants
|
10 participants
n=114 Participants
|
PRIMARY outcome
Timeframe: Baseline to Week 25Assessed by central read using Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
Outcome measures
| Measure |
Part 1- Pimicotinib(ABSK021)
n=63 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=31 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
|
|---|---|---|
|
Objective Response Rate (ORR)
|
54.0 Percentage of participants
Interval 40.9 to 66.6
|
3.2 Percentage of participants
Interval 0.1 to 16.7
|
SECONDARY outcome
Timeframe: Baseline to Week 25Population: The ITT Set consisted of participants who were randomized to a study treatment regimen.
TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either Complete Response (CR) or Partial Response (PR) as assessed by Blinded Independent Review Committee using TVS.
Outcome measures
| Measure |
Part 1- Pimicotinib(ABSK021)
n=63 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=31 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
|
|---|---|---|
|
Objective Response Rate (ORR) Per Tumor Volumn Score (TVS)
|
61.9 Percentage of participants
Interval 48.8 to 73.9
|
3.2 Percentage of participants
Interval 0.1 to 16.7
|
SECONDARY outcome
Timeframe: Baseline to Week 25Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.
Presented here is the change from baseline in ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on the measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).
Outcome measures
| Measure |
Part 1- Pimicotinib(ABSK021)
n=55 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=28 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
|
|---|---|---|
|
Change From Baseline in Active Range of Motion (ROM) at Week 25
|
15.64 Percent of range of motion
Interval 10.37 to 20.91
|
-0.07 Percent of range of motion
Interval -7.02 to 6.88
|
SECONDARY outcome
Timeframe: Baseline to Week 25Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.
The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.
Outcome measures
| Measure |
Part 1- Pimicotinib(ABSK021)
n=56 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=29 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
|
|---|---|---|
|
Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25
|
-3.00 score on a scale
Interval -3.46 to -2.55
|
-0.57 score on a scale
Interval -1.21 to 0.07
|
SECONDARY outcome
Timeframe: Baseline to Week 25Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.
Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine."
Outcome measures
| Measure |
Part 1- Pimicotinib(ABSK021)
n=56 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=29 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
|
|---|---|---|
|
Change From Baseline in Brief Pain Inventory (BPI) Worst Pain NRS Score at Week 25
|
-2.32 Score on a scale
Interval -2.73 to -1.91
|
-0.23 Score on a scale
Interval -0.8 to 0.34
|
SECONDARY outcome
Timeframe: Baseline to Week 25Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.
All participants were asked 11 or 13 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." The T-score rescales the total raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean. The T-score ranges from 0 to 100, with a higher score indicating better physical function status.
Outcome measures
| Measure |
Part 1- Pimicotinib(ABSK021)
n=56 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=29 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
|
|---|---|---|
|
Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25
|
5.63 T-score
Interval 4.21 to 7.06
|
2.23 T-score
Interval 0.23 to 4.24
|
Adverse Events
Part 1 Pimicotinib(ABSK021)
Part 1- Placebo
Serious adverse events
| Measure |
Part 1 Pimicotinib(ABSK021)
n=63 participants at risk
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1. Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=31 participants at risk
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1.
Placebo: capsule
|
|---|---|---|
|
Infections and infestations
Enterocolitis infectious
|
1.6%
1/63 • Number of events 1 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood pressure increased
|
1.6%
1/63 • Number of events 1 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Skin and subcutaneous tissue disorders
Erythema nodosum
|
1.6%
1/63 • Number of events 1 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
Other adverse events
| Measure |
Part 1 Pimicotinib(ABSK021)
n=63 participants at risk
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1. Pimicotinib(ABSK021): capsule
|
Part 1- Placebo
n=31 participants at risk
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1.
Placebo: capsule
|
|---|---|---|
|
Investigations
Alpha hydroxybutyrate dehydrogenase increased
|
25.4%
16/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Lipase increased
|
23.8%
15/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood creatine phosphokinase MB (Myocardial Band) increased
|
19.0%
12/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood creatine phosphokinase increased
|
71.4%
45/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
16.1%
5/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood lactate dehydrogenase increased
|
57.1%
36/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Aspartate aminotransferase increased
|
54.0%
34/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Amylase increased
|
34.9%
22/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Face oedema
|
47.6%
30/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Fatigue
|
28.6%
18/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
22.6%
7/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Oedema peripheral
|
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Pyrexia
|
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Asthenia
|
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Generalised oedema
|
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
General disorders
Influenza like illness
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Alanine aminotransferase increased
|
17.5%
11/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
High density lipoprotein increased
|
15.9%
10/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood creatinine increased
|
15.9%
10/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
White blood cell count decreased
|
12.7%
8/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Apolipoprotein A-I increased
|
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood cholesterol increased
|
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Neutrophil count decreased
|
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Apolipoprotein B decreased
|
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Blood alkaline phosphatase increased
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Low density lipoprotein increased
|
3.2%
2/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Urinary occult blood positive
|
1.6%
1/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Investigations
Urobilinogen urine increased
|
1.6%
1/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
52.4%
33/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Skin and subcutaneous tissue disorders
Rash
|
34.9%
22/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Eye disorders
Periorbital oedema
|
31.7%
20/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Eye disorders
Eyelid oedema
|
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Gastrointestinal disorders
Nausea
|
27.0%
17/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Gastrointestinal disorders
Diarrhoea
|
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Gastrointestinal disorders
Vomiting
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Gastrointestinal disorders
Mouth ulceration
|
1.6%
1/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Nervous system disorders
Headache
|
20.6%
13/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Nervous system disorders
Dizziness
|
15.9%
10/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
14.3%
9/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Metabolism and nutrition disorders
Decreased appetite
|
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Infections and infestations
Upper respiratory tract infection
|
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Infections and infestations
Urinary tract infection
|
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Infections and infestations
Influenza
|
4.8%
3/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
22.6%
7/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Psychiatric disorders
Insomnia
|
14.3%
9/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Vascular disorders
Hypertension
|
14.3%
9/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Renal and urinary disorders
Haematuria
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Cardiac disorders
Palpitations
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Blood and lymphatic system disorders
Anaemia
|
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
|
Reproductive system and breast disorders
Heavy menstrual bleeding
|
0.00%
0/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
|
Additional Information
Dr Yi Liu, Senior Medical Director
Abbisko Therapeutics Co, Ltd
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place